1 A general framework to support cost-efficient fecal egg

- ² count method and study design choices for large-scale STH
- 3 deworming programs monitoring of therapeutic drug
- 4 efficacy as a case study
- 5

6 **Running title:** Towards evidence-based recommendations for STH programs

7

Luc E Coffeng^{1,#,*}, Johnny Vlaminck^{2,#}, Piet Cools³, Matthew Denwood⁴, Marco Albonico⁵, Shaali M
Ame⁶, Mio Ayana^{3,7}, Daniel Dana^{3,7}, Giuseppe Cringoli⁸, Sake J de Vlas¹, Alan Fenwick⁹, Michael
French^{9,10}, Adama Kazienga², Jennifer Keiser^{11,12}, Stefanie Knopp^{11,12}, Gemechu Leta¹³, Leonardo
F. Matoso^{14,15}, Maria P. Maurelli⁸, Antonio Montresor¹⁶, Greg Mirams¹⁷, Zeleke Mekonnen⁷,
Rodrigo Corrêa-Oliveira¹⁴, Simone A. Pinto¹⁴, Laura Rinaldi⁸, Somphou Sayasone¹⁸, Peter
Steinmann^{11,12}, Eurion Thomas¹⁹, Jozef Vercruysse² and Bruno Levecke^{2,*}

14

¹ Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam,

16 The Netherlands

² Department of Translational Physiology, Infectiology and Public Health, Ghent University,
 Merelbeke, Belgium

- ³ Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University,
- 20 Ghent, Belgium
- ⁴ Department of Veterinary and Animal Sciences, University of Copenhagen, Denmark
- ⁵ National Health System, Turin, Italy
- ⁶ Laboratory Division, Public Health Laboratory-Ivo de Carneri, Chake Chake, United Republic of
- 24 Tanzania
- 25 ⁷ Jimma University Institute of Health, Jimma University, Jimma, Ethiopia
- ⁸ Department of Veterinary Medicine and Animal Production, University of Naples Federico II,
- 27 Naples, Italy
- ⁹ Schistosomiasis Control Initiative, Department of Infectious Disease Epidemiology, St Mary's
- 29 Campus, Imperial College London, London, United Kingdom
- 30 ¹⁰ RTI International, Washington DC, USA
- 31 ¹¹ Swiss Tropical and Public Health Institute, Allschwil, Switzerland
- 32 ¹² University of Basel, Basel, Switzerland
- 33 ¹³ Ethiopian Public Health Institute, Addis Ababa, Ethiopia
- 34 ¹⁴ Laboratory of Molecular and Cellular Immunology, Research Center René Rachou FIOCRUZ,
- 35 Belo Horizonte, Brazil
- 36 ¹⁵ Nursing school, Federal University of Minas Gerais, Brazil
- ¹⁶ Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva,
- 38 Switzerland
- 39 ¹⁷ Techion Group Ltd, Dunedin, New Zealand

- 40 ¹⁸ Lao Tropical and Public Health Institute, Ministry of Health, Vientiane, Lao People's Democratic
- 41 Republic
- 42 ¹⁹ Techion Group Ltd, Aberystwyth, United Kingdom
- 43
- 44 *Corresponding authors: <u>l.coffeng@erasmusmc.nl</u> (LEC) and <u>bruno.levecke@ugent.be</u> (BL)
- 45
- 46 [#]These authors contributed equally to this work.

47 Abstract

Background: Soil-transmitted helminth (STH) control programs currently lack evidence-based recommendations for cost-efficient survey designs for monitoring and evaluation. Here, we present a framework to provide evidence-based recommendations, using a case study of therapeutic drug efficacy monitoring based on the examination of helminth eggs in stool.

52 **Methods**: We performed an in-depth analysis of the operational costs to process one stool sample 53 for three diagnostic methods (Kato-Katz, Mini-FLOTAC and FECPAK^{G2}). Next, we performed 54 simulations to determine the probability of detecting a truly reduced therapeutic efficacy for 55 different scenarios of STH species (Ascaris lumbricoides, Trichuris trichiura and hookworms), pre-56 treatment infection levels, survey design (screen and select (SS); screen, select and retest (SSR)57 and no selection (NS) and number of subjects enrolled (10 - 2,000). Finally, we integrated the 58 outcome of the cost assessment into the simulation study to estimate the total survey costs and 59 determined the most cost-efficient survey design.

60 **Principal Findings:** Kato-Katz allowed for both the highest sample throughput and the lowest cost 61 per test, while $FECPAK^{G2}$ required both the most laboratory time and was the most expensive. 62 Counting of eggs accounted for 23% ($FECPAK^{G2}$) or \geq 80% (Kato-Katz and Mini-FLOTAC) of the total 63 time-to-result. *NS* survey designs in combination with Kato-Katz were the most cost-efficient to 64 assess therapeutic drug efficacy in all scenarios of STH species and endemicity.

65 **Conclusions/significance:** We confirm that Kato-Katz is the fecal egg counting method of choice 66 for monitoring therapeutic drug efficacy, but that the survey design currently recommended by 67 WHO (*SS*) should be updated. Our generic framework, which captures laboratory time and 68 material costs, can be used to further support cost-efficient choices for other important surveys

informing STH control programs. In addition, it can be used to explore the value of alternative
diagnostic techniques, like automated egg counting, which may further reduce operational costs.

71 Author Summary

72 Large-scale deworming programs are implemented worldwide to reduce morbidity caused by 73 intestinal worms. As these programs operate in resource-poor-settings, it is important that their 74 operational costs are minimized without jeopardizing the quality of decision-making. We present 75 a framework for evidence-based recommendations for cost-efficient decision-making in 76 deworming programs, using monitoring of therapeutic drug efficacy via stool examination as a 77 case study. To this end, we first assessed the time and the cost of processing stool samples in a 78 laboratory according to different diagnostic methods. Then for each diagnostic method, survey 79 design, and a range of settings (pre-dominant worm species and pre-treatment infection levels), 80 we calculated the probability of correctly detecting a truly reduced therapeutic drug efficacy and 81 the associated operational costs. Generally, the estimated operational costs varied across 82 diagnostic method, survey design, worm species and disease endemicity. Based on our findings, 83 we conclude that the use of the current diagnostic standard, the Kato-Katz method, is justified to 84 assess drug efficacy, but that a change in survey design is warranted. Our methodology, which 85 leverages detailed data on laboratory time and material costs, can also be used to provide evidence-based recommendations for other types of decisions in large-scale deworming 86 87 programs.

Key words: soil-transmitted helminths, Kato-Katz thick smear, Mini-FLOTAC, FECPAK^{G2}, cost
 analysis, preventive chemotherapy, anthelminthic resistance, egg reduction rate, survey designs

91 Introduction

92 Soil-transmitted helminths (STHs; Ascaris lumbricoides, Trichuris trichiura and the hookworm 93 species Necator americanus and Ancylostoma duodenale) infect approximately 800 million 94 individuals across the world and are responsible for the loss of more than three million disability-95 adjusted life years annually [1,2]. To control morbidity associated with these infections, the World 96 Health Organization (WHO) strives to reduce the prevalence of moderate-to-heavy intensity (MHI) 97 infections to less than 2% [3]. To reach this goal, anthelmintic drugs are periodically distributed to 98 at-risk populations through large-scale deworming programs - so-called preventive chemotherapy 99 [4]. In these programs, periodic follow-up surveys are conducted to determine whether the 100 therapeutic efficacy of the administrated drugs is still satisfactory [5], and whether stopping or 101 scaling down drug administration is justified [6]. However, as these programs often operate in 102 resource-poor settings, it is important to minimize operational costs without jeopardizing the 103 correctness of the program decisions (e.g., avoiding prematurely scaling down of preventive 104 chemotherapy or continuing the administration of anthelmintic drugs with a reduced therapeutic 105 drug efficacy). An important proportion of STH survey costs is related the processing of stool 106 samples and the counting of STH eggs under a microscope. Speich and colleagues [7] 107 demonstrated that, independent of the evaluated diagnostic method, the lion's share (~70%) of 108 the total costs of performing egg counts in Zanzibar was made up of salaries. More recently, Leta 109 and colleagues calculated those personnel salaries (~40%) and car rental fees (~50%) made up a

combined ~90% of the total study costs when doing a national STH mapping survey in Ethiopia [8].
Hence, the number of samples to be screened, the speed at which technicians can process a single
sample, the number of samples that can be processed per day, and thus the number of sampling
days, are considered the major cost drivers of programmatic surveys for infection prevalence or
therapeutic drug efficacy.

115

116 Several different microscopy-based methods (e.g., Kato-Katz thick smear (KK), Mini-FLOTAC, McMaster and FECPAK^{G2}) are used to diagnose STH infections in stool, of which some are more 117 complex than others [9-11]. Of all currently applied methods, the WHO-endorsed KK is the most 118 119 widely established. This method produces smears of 41.7 mg of stool to visualize STH eggs for 120 microscopic identification and counting [12] and is thought to be relatively easy and affordable 121 [7]. The Mini-FLOTAC employs a flotation solution to separate STH eggs from stool debris in a special device prior to counting [9]. The FECPAK^{G2} method is the most recent and innovative 122 123 diagnostic method [11, 13, 14]. It is also a flotation-based method, but instead of using a standard 124 microscope, it employs a purpose-made device to accumulate STH eggs in one field of view, and 125 to produce a digital image of this view that can later be marked up by a technician [11]. However, in a previous study, it was shown that both FECPAK^{G2} and Mini-FLOTAC had a clinical sensitivity 126 127 equal or inferior to a single KK for all STHs [15], and that these flotation-based methods provided lower fecal egg counts (FECs; expressed as eggs per gram of stool (EPG)) compared to KK [16]. 128

129

130 Making an evidence-based choice about which FEC method to use in STH control programs 131 remains non-trivial, particularly when a decision-making framework is intended to be applied to a

wide range of epidemiological settings. This is because the suitability and the cost of different 132 133 survey designs and diagnostic techniques will vary by epidemiological setting [17]. For instance, 134 the probability of making correct policy decisions may strongly depend on both the performance 135 of a particular diagnostic method and the associated decision criterion in a particular 136 epidemiological setting [18-23]. For STH, this performance depends on the average intensity of 137 infection in a community as well as the level of variation in egg excretion (between individuals and 138 within individuals over time), and in the case of the evaluation of drug efficacy, variation in 139 individual drug responses [20,23]. Further, it is important to consider that the total operational 140 cost of a survey will depend on the consumable costs of the diagnostic method used, the survey 141 design (number of samples and number of days spent in the field), and the time needed to count 142 eggs [20]. Importantly, the latter will depend on how many eggs need to be counted, which has 143 not been considered before and which will vary by epidemiological setting and will depend on the 144 goal of the survey (e.g., detecting infection (counting at least one egg) or quantifying intensity of 145 infection (counting all eggs)). Quantifying these costs requires an in-depth analysis of the 146 operational costs of processing samples with different FEC methods.

147

We aim to provide a general framework for evidence-based recommendations for cost-efficient decision-making in large-scale STH deworming programs based on FEC methods, using monitoring of therapeutic drug efficacy as a case study. To this end, we performed an in-depth analysis of the operational costs to process one sample for three FEC methods (KK, Mini-FLOTAC and FECPAK^{G2}) based on the time-to-result and an itemized cost assessment. Next, we performed a simulation study to determine the probability of correctly concluding that the therapeutic drug efficacy is

reduced based on different FEC methods, survey designs and numbers of individuals enrolled, while accounting for the variation in both egg counts and individual drug responses. Finally, we integrated the outcome of the in-depth cost-assessment into the simulation study to determine the most cost-efficient diagnostic test and survey design to detect presence of reduced drug efficacy for the different STH species across different scenarios of STH endemicity.

159 Methods

160 Ethics statement

161 Data were collected from four sites during a drug efficacy trial designed to test the equivalence of 162 different FEC methods in attaining estimates of the therapeutic efficacy of a single oral dose of 163 400 mg albendazole (ALB) against STH infections in school aged children (SAC) [24]. The trial was 164 performed in Brazil, Ethiopia, Lao PDR and Zanzibar (Pemba Island). The study protocol for this 165 trial were reviewed and approved by the Ethics Committee of the Faculty of Medicine and Health Sciences, the University Hospital of Ghent University, Belgium (Ref. No B670201627755; 166 167 2016/0266) and the national ethical committees associated with each trial site (Ethical Review Board of Jimma University, Jimma, Ethiopia: RPGC/547/2016; National Ethics Committee for 168 169 Health Research (NECHR), Vientiane, Lao PDR: 018/NECHR; Zanzibar Medical Research and Ethics 170 Committee, United Republic of Tanzania: ZAMREC/0002/February/2015; and the Institutional 171 Review Board from Centro de Pesquisas René Rachou, Belo Horizonte, Brazil: 2.037.205). The trial 172 was retrospectively registered on Clinicaltrials.gov (ID: NCT03465488) on March 7, 2018.

In-depth analysis of the operational costs to process one sample for three FEC
methods based on the time-to-result and an itemized cost assessment

175 Time-to-result


Measuring time-to-result for the different FEC methods was part of the drug efficacy trial, which have been extensively described elsewhere [24,25]. During the trial, baseline stool samples were collected from SAC, who were subsequently treated with a single dose of 400 mg ALB. Between 14 and 21 days after treatment, SAC who were positive for any STH species at baseline were resampled to evaluate the reduction in egg output (ERR). At baseline and follow-up, stool samples were processed by duplicate KK (slide A and B), Mini-FLOTAC and FECPAK^{G2} to determine FECs (expressed in EPG) for each STH separately.

183

Upon arrival in the laboratory, stool samples were first grouped into batches of ten samples (with the remainder in a separate last batch). Subsequently, all stool samples were homogenized by stirring with a wooden tongue depressor. Finally, subsamples were taken to be processed according to the different FEC methods. **Fig 1** provides an overview of the different steps timed for each FEC method, including preparing the sample for analysis, counting eggs and data entry (demographic data and FECs), which ultimately resulted in the time-to-result measurement.

Fig 1. Overview of the different operational steps for the different FEC methods. The distinctive steps to perform a Kato-Katz (KK), Mini-FLOTAC or FECPAK^{G2} on a single stool sample are provided in chronological order per method. The procedures are grouped per main subject (blue: entry of demographic data; green: preparation of the sample; yellow: reading of the slide/device or the image to count STH eggs; red: entry of fecal egg count data). Waiting steps included in the procedure are indicated in grey and represent a fixed amount of time. The small clock symbol indicates what steps have been timed as part of this experiment.

196



197 198

Detailed standard operating procedures (SOPs) to time the preparatory steps and the egg counting process are described elsewhere (see S3-5 info of Vlaminck *et al.* [24]); **S1 Info** provides a brief summary). A summary of the SOP to time the data entry is provided in **S2 Info**.

202 We expressed the time (in seconds) needed to enter data and prepare samples for analysis per

203 batch by dividing the total time recorded per batch by the number of samples within that batch.

These calculations included batches gathered at baseline and follow-up. Batches containing fewer 204 205 than 5 samples were not timed and were excluded from these calculations. We report the average 206 reading time, preparation time and data entry time across batches. The overall mean preparation 207 time per sample was calculated as the mean of batch-specific estimates of time per sample. The 208 data on the timing of egg counting were analyzed at the level of samples. For each FEC method, 209 the correlation between the time required to count and the absolute number of eggs in the sample 210 was quantified using linear regression models. In these models, we predicted the log₁₀-211 transformed time (in seconds) needed for egg counting (dependent variable) using the square of the log₁₀-transformed total number of STH eggs counted plus 1 as the independent variable. 212 213 Statistical analyses were conducted in R [26], Microsoft Excel v16.16.7 and Prism version 6.0. for 214 Mac.

215

216 Itemized cost assessment

We calculated the cost of materials to collect a stool sample in a school setting and the costs to 217 218 perform the FEC method, including the required equipment, supplies and reagents. For this, we 219 performed an itemized cost assessment considering the cost per unit, the usage over a one-year 220 period and the expected duration of use (in years). A detailed itemized cost assessment to collect stool samples and to perform the FEC method is provided in S3 Info. For specific items, such as 221 the KK kit, Mini-FLOTAC or FECPAK^{G2} devices, we used the prices that were either advertised online 222 223 or obtained through the manufacturer (2020). To estimate the cost of everyday materials, such as 224 scissors, paper, salt and buckets, Ethiopian market prices were used (2020).

225

226 Simulation study to assess the probability of correctly detecting a truly reduced

227 therapeutic efficacy

228 Definition of a reduced therapeutic efficacy and survey designs

For each candidate survey design, we determined the probability that the resulting ERR pointestimate confirmed the presence of reduced efficacy of a single oral dose of 400 mg ALB. Here, we assumed that the true efficacy was 5%-points under the species-specific thresholds specified by WHO (**Table 1**) [5], and we concluded the presence of reduced therapeutic efficacy if the ERR point-estimate was under the WHO threshold. Given that the endemicity at baseline has an impact on the statistical power [27] and the total survey costs [21], we determined the probability of correctly detecting a truly reduced therapeutic efficacy across different scenarios of endemicity.

236

237 Currently, it is recommended by WHO to determine the efficacy based on individuals that were 238 egg-positive at baseline only; however, excluding individuals who were egg-negative at baseline 239 from the analysis may result in a substantial overestimation of drug efficacy due to regression to 240 the mean, particularly in low endemic settings or when true drug efficacy is low. Coffeng and 241 colleagues showed previously that this bias could be avoided by a number of alternative survey 242 designs [21]. However, an in-depth analysis of the associated operational costs was missing. Here, we re-evaluate some of the survey designs assessed by Coffeng and colleagues, including the 243 WHO-recommended 'screen and select' design (SS; only egg-positive individuals are followed up), 244 245 the 'screen, select, and retest' (SSR; only egg-positive individuals are followed up, but the analysis 246 is based on a second separate baseline stool sample [21]), and the 'no selection' design (NS; all 247 enrolled individuals are screened at baseline and follow-up). For the NS and SSR survey design,

we explored two variants, one that was based on a single FEC on the follow-up sample ($NS_{1\times 1/1\times 1}$ 248 249 and $SSR_{1\times 1/1x1}$), and one that was based on duplicate FECs ($NS_{1\times 1/1x2}$ and $SSR_{1\times 1/1x2}$). We did 250 not consider survey designs based on a single FEC on two consecutive stool samples at follow-up 251 FEC ($NS_{1\times 1/2x1}$ and $SS_{1\times 1/2x1}$), as sample collection on two consecutive days adds considerable 252 logistical issues while yielding relatively little in terms of precision in drug efficacy estimates [21]. 253 For the WHO-recommended SS design we considered two variants: one based on a single FEC 254 both at baseline and follow-up ($SS_{1\times 1/1\times 1}$), and one based on duplicate FECs at both time points 255 $(SS_{1\times 2/1\times 2})$. The former is recommended in the WHO manual to monitor the therapeutic efficacy 256 of drugs against schistosomes and STH [5], and the latter is currently being piloted in a number of 257 endemic countries as part of the Starworms project [27]. 258 259 General simulation framework For the current simulation study, we adapted the framework described by Coffeng and colleagues 260 261 [21], accounting for the following sources of variation in egg counts: 1. Inter-individual variability in mean egg intensity due to variation in infection levels 262 263 between individuals (assumed to follow a gamma distribution);

- 264 2. Day-to-day variability in mean egg intensity within an individual due to heterogeneous
- 265 egg excretion over time (assumed to follow a gamma distribution);
- 266 3. Variability in egg counts between repeated aliquots of a stool sample due to the
- aggregated distribution of eggs in stool (assumed to follow a Poisson or a gamma-Poisson
- 268 (i.e., negative binomial) distribution);

- 269 4. Inter-individual variability in the effect of drug administration in terms of the ERR
- 270 (assumed to follow a beta distribution).

For the quantification of each gamma distribution, we followed the approach of Denwood et al 271 [28] in using the coefficient of variation (cv) as a standardised measure of variability, which is 272 related to the shape parameter k of a gamma distribution by taking $k = cv^{-2}$. Species-specific 273 274 variability between individuals and within individuals over time were estimated based on data 275 from clinical trials during which a duplicate KK was performed on two consecutive stool samples 276 both at baseline and follow-up [29]. STH species and FEC method-specific variability between 277 repeated aliquots of the same stool sample were estimated from the egg count data published by 278 Cools et al. [30]. The average difference between FEC methods in terms of egg recovery 279 performance was also determined as flotation techniques are know to miss unfertilized eggs [31] 280 (see S4 Info for details). The parameterization of the simulation framework is summarized in Table 281 1. For a detailed description of the simulation model we refer to S5 Info.

Parameter	Ascaris	Trichuris trichiura	Hookworm
	lumbricoides		
Mean EPG in the population (μ) as			
measured by KK			
Endemicity level 1: 1.0 - 9.9%	9.6	2.8	3.7
Endemicity level 2: 10.0 - 19.9%	85.2	12.9	23.7
Endemicity level: 20.0 - 49.9%	360.0	49.7	61.7
Endemicity level: 50.0 - 100.0%	2195.5	124.7	210.3
Variability in EPG between individuals	0.327	0.444	0.250
(shape k_i)			
Day-to-day variability in EPG within	0.510	1.000	1.000
individuals (shape k_d)			
Weight of stool aliquot (w_s ; gram)			
КК	1/24	1/24	1/24
Mini-FLOTAC	1/10	1/10	1/10
FECPAK ^{G2}	1/34	1/34	1/34
Relative recovery of eggs from stool (ρ_s)			

Parameter	Ascaris	Trichuris trichiura	Hookworm
	lumbricoides		
KK (reference)	1.000	1.000	1.000
Mini-FLOTAC	0.645	1.005	0.801
FECPAK ^{G2}	0.248	0.152	0.569
Variability in egg counts between aliquots			
based on the same stool sample (shape			
k_s)			
КК	∞*	∞*	∞*
Mini-FLOTAC	0.579	3.022	1.465
FECPAK ^{G2}	0.520	0.706	0.574
Assumed true mean and variability (95%-	0.80 (0.69–0.89)	0.35 (0.25–0.45)	0.75 (0.64–0.84)
CI) in drug efficacy (beta distribution with			
shape parameters $lpha_{ m ERR}$ and $eta_{ m ERR}$)			
$lpha_{ m ERR}$	49.5	30.2	53.8
$\beta_{ m ERR}$	12.4	56.1	17.9
WHO definition for reduced therapeutic	<85%	<40%	<80%
efficacy based on ERR [5]			

* Implies $cv_{KK} = 0$, which means that KK-based egg counts from repeated aliquots of the same homogenized stool sample follow a Poisson distribution (no extra over-dispersion in contrast to Mini-FLOTAC or FECPAK^{G2}).

286

287 Using this framework, we simulated egg counts for all survey designs across four scenarios, each 288 representing different population average baseline FECs. The selection of these scenarios was 289 based on infection levels in the nationwide mapping of STH infections in Ethiopia [32] (see also Fig. 290 S1), where each scenario represented the median of school-level mean FEC (in EPG) of one of four endemicity levels (prevalence between 1.0 and 9.9%, 10.0 and 19.9%, 20.0% and 49.9%, or 291 292 ≥50.0%). For each survey design, we considered a range of 100 to 5,000 individuals (with 293 increments of 5 individuals) that are initially tested at baseline. For each survey design, sample 294 size and endemicity scenario, 10,000 repeated Monte Carlo simulations were performed. In each 295 simulation, the group-based arithmetic mean ERR was calculated using the recommended 296 procedure [33], and the ERR was considered reduced if under the STH species-specific threshold (Table 1). For each survey design and sample size, we then calculated the proportion of the 10,000 297 298 repeated Monte Carlo simulations that correctly identified therapeutic efficacy as truly reduced 299 $(prob_{reduced})$. If a baseline survey resulted in fewer than 50 egg-positive individuals, the survey

300 was considered to have failed and was discontinued. In those cases, it was considered to not have 301 detected reduced efficacy. In the remainder of the text, the proportion of surveys that fail will be 302 referred to as the "failure rate". All simulations and calculations were performed using the eggsim 303 package [19] in R [26]. This package allows the same calculations to be made for any arbitrary set 304 of parameter values using highly performant C++ code, and is freely available [34].

305

306 Total operational costs to monitor drug efficacy

307 For each simulated survey, we calculated the total operational costs in terms of (i) the cost of 308 consumables to collect and process samples, (ii) the salary for a single mobile field team comprised 309 of one nurse and three laboratory technicians, and (iii) the cost of transport, including car rental, 310 salary of the driver, and gasoline. We assumed that a working day consists of 8 working hours, and 311 that the daily salary of one team was 80 US\$ (4 per diems of 22.5 US\$) and that the daily cost for 312 transport was 90 US\$. Second, we assumed that the team collected samples in the morning (8:00 -12:00), and that all collected samples were processed in the afternoon (13:00 - 17:00). Complete 313 314 analysis of all samples on the same day implies that the number of samples that can be collected 315 daily is limited, and that this number will vary across FEC methods, phase of the trial (less time for 316 egg counting is required in follow-up samples) and endemicity (more time for egg counting is 317 required in highly endemic areas). Note that we do not consider costs for the establishment and 318 maintenance of laboratory infrastructure. We further assumed that all work takes place on regular 319 working days, that the team does not take any breaks during processing, and that all samples are 320 collected from a single school/community without loss to follow-up. All cost calculations were

based on the itemized cost-assessment described above. Technical details on how the total costs
were calculated can be found in S6 Info.


323

324 **Results**

325 Time-to-result

326 During the drug efficacy trial surveys performed in Brazil, Ethiopia, Lao PDR, and Tanzania, we assessed the mean time-to-result (i) to prepare stool samples $(T_{prep,X}, X \text{ representing the number})$ 327 of aliquots per sample), (ii) to count eggs, (iii) to digitize demographic data ($T_{demography}$), and (iv) 328 to digitize the FEC results ($T_{record.X}$). The time analysis is illustrated in **Fig 2**. Overall, a duplicate KK 329 330 consumed the most time, requiring on average (standard deviation) 989 sec (449). A single KK 331 consumed the least amount of time and required on average 507 sec (318). The mean time-toresult for a single Mini-FLOTAC or FECPAK^{G2} method were 786 sec (513) and 802 sec (329), 332 respectively. The percentage of time-to-result spent on the egg counting process was 333 334 approximately 80% for both KK (single KK: 413 sec out of 507sec; duplicate KK: 820 sec out of 989 sec) and Mini-FLOTAC (632 sec out of 786 sec), while this was 23% for FECPAK^{G2} (185 sec out of 335 336 802 sec). For the latter method, most of the time-to-result (74%) was spent preparing the samples for analysis (596 sec out of 802 sec). 337

Fig 2: Time required to quantify soil-transmitted helminth infections in stool by four fecal egg count methods. The height of the bars represents the mean time (in sec) needed to enter demographic data (blue), to perform the preparation phase (green), to count eggs (yellow) and to enter egg count data (red) for a single (1xKK) and duplicate Kao-Katz (2xKK), Mini-FLOTAC (MF) and FECPAK^{G2} (FP). The relative proportion (in %) of total time required to perform the preparation phase and to count is reported inside the bars.




344

345

As expected, counting a larger number of STH eggs required more reading time, where the log transformed total time required to count all eggs could be well described as a linear function of the square of the base-10 log-transformed total egg counts (**Fig 3**). **Table 2** summarizes the average time required for the different steps included in the total survey costs for each FEC

350 method separately. To obtain an estimate for a single KK preparation we divided the average time 351 to prepare a duplicate KK (135 sec) by two (= 67 sec). As a second Mini-FLOTAC can be filled from 352 the same Fill-FLOTAC (no need to weigh and homogenize the sample for a duplicate Mini-FLOTAC), 353 we multiplied the mean time required to process a single Mini-FLOTAC (131 sec) by 1.5 to estimate 354 the time for a duplicate Mini-FLOTAC (197 sec). To estimate the time for a duplicate FECPAK^{G2}, we 355 doubled the time for each of the different preparatory steps, except for the step to prepare the samples in the FECPAK^{G2} sedimenters, resulting in a total time of 1,050 sec (= 142 sec + 2 x 174 356 357 sec + 2 x 280 sec). Similarly, the mean time needed to enter one duplicate KK result was 18 sec; 358 the time needed to record FEC results based on single KK and Mini-FLOTAC was assumed to be half that value (9 sec). For the FECPAK^{G2} method, no FEC data entry was required as the software 359 360 automatically registers and stores mark-up data. S7 Info provides more detailed information 361 (number of batches timed; the average units per batch; average and SD time) on each step of the 362 sample analysis process, starting with the timing of the demographic data entry followed by the 363 preparation phase, the egg counting process, and the time it took to enter FEC data.

Fig 3. The reading time as a function of the number of STH eggs counted in a sample. This figure represents the reading time as a function of the number of STH eggs counted in a sample for single Kato-Katz (KK), Mini-FLOTAC and FECPAK^{G2} separately. All egg counts represent raw egg counts (not in eggs per gram of stool).
 The red line represents the linear regression line. The function of the regression line is also provided.



Symbol	Description	Average time required (seconds)			
		КК	Mini-FLOTAC	FECPAK ^{G2}	
T _{demography}	Time to enter demographic data	15	15	34	
$T_{prep,X}$	Time to prepare a stool sample				
X = 1	One aliquot	67	131	596	
X = 2	Two aliquots	135	197	1,050	
f(c)	Time required to count <i>c</i> eggs	10^(2.3896	10^(2.5154	10^(1.8349	
	(not EPG) in a single aliquot	+ 0.0661	+ 0.0661	+0.1731	
		$\times \log_{10}(c+1)^2)$	$\times \log_{10}(c+1)^2)$	$\times \log_{10}(c+1)^2$	
$T_{record,X}$	Time to record count data				
X = 1	One aliquot	9	9	0	
X = 2	Two aliquots	18	18	0	

370	Table 2. Overview of parameters that determine the time required to process a single stool sample.
-----	--

371

372 Itemized cost assessment

373	The costs associated with the materials for stool sample collection in schools and to process stool
374	samples for a single or duplicate KK, mini-FLOTAC and FECPAK ^{G2} are reported in detail in Table 3 .
375	In summary, the costs associated with sampling a single sample ($cost_{sample}$) was US\$ 0.57. The
376	material costs to perform a single FEC ($cost_{aliquot,1}$) were US\$ 1.37 for KK, US\$ 1.51 for the mini-
377	FLOTAC method, and US\$ 1.69 for the FECPACK ^{G2} method. When a duplicate FEC was performed
378	on the same sample the material costs ($cost_{aliquot,2}$) were US\$ 1.51 (KK), US\$ 1.87 (Mini-FLOTAC),
379	and US\$ 2.73 (FECPAK ^{G2}).

Symbol	Description	Cost (US\$)		
		КК	Mini-FLOTAC	FECPAK
$cost_{sample}$	Cost of collecting a single stool sample	0.57	0.57	0.57
cost _{aliquot,X}	Cost per aliquot when preparing X aliquots from the same stool sample			
X = 1	One aliquot	1.37	1.51	1.69
X = 2	Two aliquots	1.51	1.87	2.73
salary _{perdiem}	Daily salary for every technician and nurse on the mobile Team	22.50	22.50	22.50

Symbol	Description	Cost (US\$)		
		КК	Mini-FLOTAC	FECPAK ^{G2}
travel _{perdiem}	Daily cost of car rental, including petrol and driver wages	90.00	90.00	90.00

382

Failure rate, probability of correctly detecting reduced therapeutic efficacy and thecorresponding total survey costs

385 Given the large number of possible scenarios (981 sample sizes x 6 study designs x 4 levels of 386 endemicity x 3 FEC methods x 3 STH species = 211,896 scenarios), and the different output 387 parameters (failure rate, $prob_{reduced}$ and $cost_{total}$), we first illustrate the performance of only 388 KK-based survey designs in areas that are low endemic for hookworm(mean FEC = 3.7 EPG) (Fig 4). Fig 4A shows that the failure rate, i.e., the risk of observing fewer than 50 egg-positive 389 390 individuals at baseline, is high (> 25%) when < 250 subjects were enrolled. For sample sizes of 391 about 250 to 750 subjects, the failure rate was lower for a $SS_{1\times 2/1x2}$ survey design compared to 392 the other survey designs, as duplicate KK results in higher sensitivity for detecting at least one egg 393 in the baseline samples. To reduce the failure rate to < 1%, at least 440 individuals needed to be 394 enrolled for a $SS_{1\times 2/1x2}$, while this was at least 690 for the other survey designs. For the NS and 395 SSR survey designs, the probability of correctly detecting reduced drug efficacy (prob_{reduced}) 396 increased with the number of individuals enrolled (Fig 4B) but varied between these survey 397 designs. For example, when 700 individuals were recruited the $prob_{reduced}$ equalled 84% for 398 $NS_{1\times 1/1x2}$, 79% for $NS_{1\times 1/1x1}$, 71% for $SSR_{1\times 1/1x2}$ and 67% for $SSR_{1\times 1/1x1}$. For SS surveys, 399 prob_{reduced} did not increase beyond 6% and decreased again with increasing sample sizes over


400 400, which is driven by the increasingly precise (due to sample size) but systematically 401 overestimated drug efficacy (due to regression towards the mean).

402

403 Regarding the total survey costs (Fig 4C), $NS_{1\times 1/1x2}$, $NS_{1\times 1/1x1}$ and $SS_{1\times 2/1x2}$ were the most 404 expensive survey designs, while the two SSR designs and $SS_{1\times 1/1x1}$ were the cheapest. For 405 example, when enrolling 700 individuals, the mean total survey cost ($cost_{total}$) was 5,853 US\$ for 406 $NS_{1\times 1/1x2}$, 4,861 US\$ for $NS_{1\times 1/1x1}$ and 4,017 US\$ for $SS_{1\times 2/1x2}$, while for the two SSR designs and $SS_{1\times 1/1x1}$ the mean $cost_{total}$ ranged from 2,737 US\$ to 3,157 US\$. To determine the most 407 cost-efficient survey design, we plotted $prob_{reduced}$ as a function of mean $cost_{total}$ (Fig 4D) and 408 verified which survey design maximized the $prob_{reduced}$ for a given mean $cost_{total}$. For survey 409 410 budgets of up to 2,600 US\$, either SSR survey design maximized the $prob_{reduced}$ (lines overlay each other), while for survey budgets between 2,600 US\$ and 4,200 US\$, $NS_{1\times1/1x1}$ yielded the 411 412 highest *prob_{reduced}*. When more budget was available, *NS* surveys were more cost-efficient. For 413 budgets between 4,200 and 5,200 US\$, $NS_{1\times 1/1x1}$ resulted in the highest $prob_{reduced}$, whereas a 414 budget of 5,200 US\$ and above, the NS survey variant deploying a duplicate KK at follow-up 415 $(NS_{1\times 1/1x2})$ was the most cost-efficient. To achieve a <20% risk of falsely concluding adequate 416 drug efficacy ($prob_{reduced} \ge 80\%$), we can see from Fig 4D that $NS_{1\times 1/1x1}$ achieves this $prob_{reduced}$ at the lowest cost (red line; mean $cost_{total}$ = 5,000 US\$), with the $NS_{1\times 1/1x2}$ as a 417 close runner-up (beige line; mean $cost_{total}$ = 5,200 US\$). For a target value of $prob_{reduced} \ge$ 418 419 82%), $NS_{1 \times 1/1x2}$ was always the most cost-efficient survey design.

Fig 4: The failure rate, the probability of correctly concluding reduced drug efficacy and the total survey cost across six survey designs. This figure shows the impact of the survey design and sample size on the failure rate (Panel A), probability of correctly detecting truly reduced efficacy ($prob_{reduced}$; Panel B) and the mean total survey cost ($cost_{total}$; Panel C). To gain more insights into the most cost-efficient survey design, the probability of correctly detecting reduced drug efficacy $prob_{reduced}$ was plotted as a function of the mean $cost_{total}$ (Panel D). For each of the four panels, we only consider the use of Kato-Katz in areas with low levels of hookworm infection (mean FEC = 3.7

426 EPG). NS = no selection; SS = screen and select; SSR = screen, select, and retest. Note, for panel A, all survey designs
 427 other than SS1x2/1x2 are identical to SSR1x1/1x2.




429 Second, we explored the impact of the different FEC methods across the six survey designs for 430 hookworms in the same endemicity level as above (Fig 5). Generally, deploying Mini-FLOTAC and FECPAK^{G2} did not greatly improve the $prob_{reduced}$ for SS survey designs. For the other survey 431 432 designs, Mini-FLOTAC and KK achieved were equally cost-efficient (lines are close to each other). For Mini-FLOTAC, the cheapest survey design to obtain a $prob_{reduced} \ge 80\%$ was an $NS_{1\times 1/1x2}$ 433 survey based on 495 individuals, at a cost of 5,246 US\$ (S6 Fig). For KK, this was $NS_{1\times 1/1x1}$ based 434 on 730 individuals at a cost of 4,987 US\$ (Fig 4). For FECPAK^{G2}, the $prob_{reduced}$ remained below 435 85.2%, even when both sample size (2,000) and available budget (27,140 US\$) were maximized 436

437 (see **S7 Fig** for details on the impact of sample size).

438 Fig 5. The probability of correctly detecting presence of reduced drug efficacy and the total survey cost for three FEC

methods across six survey designs. This figure plots the probability of correctly identifying reduced therapeutic efficacy ($prob_{reduced}$) as a function of the mean total survey costs ($cost_{total}$) for the three different FEC methods (Kato-Katz thick smear (KK), Mini-FLOTAC and FECPAK^{G2}; colored lines) and six survey designs (different panels). For each panel, we only consider areas that are low endemic for hookworm (mean FEC = 3.7 EPG). NS = no selection; SS = screen and select; SSR = screen, select, and retest.



444

When redrawing **Figs 4** and **5** for the other two STH species at the corresponding low endemicity level (*A. lumbricoides*: mean FEC = 9.6 EPG, **Figs S2 – 3**; *T. trichiura*: mean FEC = 2.8 EPG, **Figs S4 – 5**), we noted three important differences compared to hookworm. First, the risk for a failed survey was remarkably lower for *A. lumbricoides*. While the failure rate is 8.5% when 250 subjects are enrolled for a survey ($SS_{1\times 2/1x2}$) targeting *A. lumbricoides* (**Fig S2A**), this was 98.7% and 97.4% for *T. trichiura* (**Fig S4A**) and hookworms (**Fig 4A**), respectively. As a consequence of this, the mean

451	$cost_{total}$ and the sample size at which $prob_{reduced} \geq 80\%$ was lower compared to the other
452	STHs (A. lumbricoides: Fig S2D: $NS_{1\times 1/1x1}$ at mean $cost_{total}$ = 2,522 US\$; T. trichiura: Fig S4D:
453	$NS_{1 \times 1/1x2}$ at mean $cost_{total}$ = 19,628 US\$; Hookworm: Fig 4D: $NS_{1 \times 1/1x1}$ at mean $cost_{total}$ =
454	4,987 US\$). Second, in contrast to hookworms, where $prob_{reduced}$ for a given budget differed
455	only marginally between Mini-FLOTAC and Kato-Katz thick smear (Fig 5), the differences FEC
456	methods were more substantial for A. lumbricoides and T. trichiura). For A. lumbricoides (Fig S3),
457	KK provided the highest $prob_{reduced}$ for the same budget, while this was Mini-FLOTAC for T.
458	trichiura (Fig S5). Third, none of the survey designs achieved a $prob_{reduced} \ge 80\%$ for T. trichiura,
459	given the maximum simulated sample size of 2,000 individuals (Fig S4B).

460


461 In Fig 6, we show the impact of pre-treatment endemicity on the probability of correctly identifying 462 reduced drug efficacy based on KK. When surveys were conducted in higher levels of endemicity, a higher prob_{reduced} was obtained for the same budget. Although this was observed for all three 463 464 STH species and all six survey designs, this increase was most distinct for SS survey designs. This 465 was to be expected as the bias due to regression towards the mean in SS survey designs is known 466 to decrease with higher infection levels. Although SS survey designs rarely resulted in a correct detection of a truly reduced therapeutic drug efficacy when endemicity levels were low (top row 467 468 panels Fig 6), they almost reach the highest $prob_{reduced}$ at a cost of the cheapest survey design 469 at the highest levels of endemicity for both A. lumbricoides and hookworms (bottom row panels 470 Fig 6). For *T. trichiura*, the performance of *SS* survey designs remained relatively poor, which is 471 logical as the regression towards the mean is expected to be higher when true drug efficacy is 472 lower (45% for *T. trichiura* in the simulations). This figure also highlights a shift in the most cost-

- 473 efficient survey design: while at low level of endemicity, the most cost-efficient survey design
- 474 depends on the available funds, for higher endemicities, only the $NS_{1\times 1/1x1}$ survey design
- 475 maximizes the $prob_{reduced}$ for any available budget.

476 Fig 6. The probability of correctly detecting presence of reduced drug efficacy and the total survey cost for six survey

477 designs across four levels of endemicity when deploying Kato-Katz. This figure plots the probability of correctly 478 identifying reduced therapeutic efficacy ($prob_{reduced}$) as a function of the mean total survey costs ($cost_{total}$) across

six survey designs for the three soil-transmitted helminth species and four levels of endemicity (see **Table 1**).



480

482	In Table 4, we provide the sample size and mean $cost_{total}$ for those survey designs that detected
483	reduced efficacy with $prob_{reduced}$ ~80% at the lowest cost for each of the different STH species.
484	Generally, this table confirms that the $NS_{1 imes1/1x1}$ survey design in combination with KK was the
485	most cost-efficient choice to assess therapeutic drug efficacy in all scenarios of STH species and
486	endemicity. Only when surveys were conducted in areas where endemicity of T. trichiura
487	infections were low, the $NS_{1 imes1/1x2}$ survey combined with Mini-FLOTAC was more cost-efficient.

488

STH species	Mean FEC (EPG)	Survey design	FEC method	Sample size	Mean <i>cost_{total}</i> (US\$
A. lumbricoides					
	9.6	$NS_{1 \times 1/1 \times 1}$	Kato-Katz	380	2,522
	85.2	$NS_{1 \times 1/1 \times 1}$	Kato-Katz	165	1,358
	360.0	$NS_{1 \times 1/1 \times 1}$	Kato-Katz	145	1,282
	2195.5	$NS_{1 \times 1/1 \times 1}$	Kato-Katz	135	1,243
T. trichiura		,			
	2.8	$NS_{1 \times 1/1 x 2}$	Mini-FLOTAC	1,680	17,313
	12.9	$NS_{1\times 1/1x1}$	Kato-Katz	1,215	8,134
	49.7	$NS_{1 \times 1/1 \times 1}$	Kato-Katz	830	5,740
	124.7	$NS_{1\times 1/1x1}$	Kato-Katz	790	5,523
Hookworms		,			
	3.7	$NS_{1 \times 1/1 \times 1}$	Kato-Katz	730	4,987
	23.7	$NS_{1 \times 1/1 \times 1}$	Kato-Katz	245	1,666
	61.7	$NS_{1 \times 1/1 \times 1}$	Kato-Katz	185	1,437
	210.3	$NS_{1 \times 1/1 x 1}$	Kato-Katz	160	1,340

νδα

490

Discussion 491

492 In this paper, we present new evidence-based recommendations for cost-efficient monitoring of 493 therapeutic drug efficacy against STH, using a simulation framework that captures important interactions between STH epidemiology (variability in egg counts due to various sources), 494 diagnostic test performance (species- and method-dependent egg recovery and count variability), 495

survey design (bias and accuracy that change with endemicity) and operational costs (which 496 497 change with endemicity, diagnostic method and survey design). With this framework, we address 498 the challenge of minimizing operational costs of STH monitoring in resource-limited settings 499 without jeopardizing the quality of the decision-making. We performed an in-depth analysis of the 500 operational costs to process one sample for three FEC methods (KK, Mini-FLOTAC and FECPAK^{G2}) 501 based on the time-to-result and an itemized cost assessment. Next, we simulated how the 502 probability of correctly detecting reduced therapeutic drug efficacy depends on different FEC 503 methods and survey designs, accounting for sources of variation in egg counts as quantified based 504 on several STH datasets. Finally, we integrated the outcome of the in-depth cost-assessment into 505 the simulation study and determined the most cost-efficient survey design to detect presence of 506 reduced drug efficacy across different scenarios of STH endemicity. Overall, we confirm that KK is 507 the best FEC method to monitor therapeutic drug efficacy, but that the survey design currently 508 recommended by WHO should be updated.

509

510 Single KK is the cheapest and least time-consuming method

The mean time and cost for material to process one sample varied from ~8.5 min (single KK) to ~16.5 min (duplicate KK), and from US\$ 1.37 (single KK) to US\$ 1.69 (FECPAK^{G2}). Our study found that a single KK is both the cheapest and least-time consuming of the three FEC methods evaluated. Although a comparison across studies is not straightforward, as differences in laboratory time can be explained by differences in endemicity (laboratory time varies significantly with the number of eggs counted) and level of expertise of laboratory technicians (laboratory time

517 was lower when technicians were more acquainted with the FEC method; data not shown), other 518 researchers generally reported a similar laboratory time for both single ([35: ~9.5 min; [36]; ~11.0 519 min; [37]: ~5.0 min) and duplicate KK ([35]: ~16.6 min). The cost for material estimated in the 520 current study (single KK: US\$ 1.95; duplicate KK: US\$ 2.17), were higher than those reported by Speich et al. [35] (single KK: US\$ 0.03; duplicate KK: US\$ 0.04). These differences can be explained 521 522 by the fact that we included fixed survey costs (0.60 US\$, e.g., gloves and permanent markers). In 523 addition, while Speich et al [35] re-used the templates for 50 samples, we opted for single use of 524 materials as there was only limited mesh and cellophane in one kit. For the other two FEC methods, the laboratory time and cost for material were ~13.1 min and US\$ 1.51 for Mini-FLOTAC, 525 and ~13.5 min and US\$ 1.69 for FECPAK^{G2}. However, data on laboratory time and cost for material 526 527 to compare our results are either scarce (Mini-FLOTAC: 8 – 12 min [38]) or absent (FECPAK^{G2}). It is 528 also important to note that our estimates of laboratory time and material costs did not include the washing of devices, and that we based our costs based on an Ethiopian market in 2020. 529

530

531 Revision of the WHO guidelines to monitor drug efficacy is warranted

532 WHO currently recommends a selection and screen approach during which a single stool sample 533 is processed by a single KK both at baseline and follow-up [5]. Although our study confirms that KK 534 is the FEC method of choice, it indicates that the recommended survey design will often result in 535 poor decision-making due to overestimation of drug efficacy (because of regression towards the 536 mean) at a relatively high cost. Instead, a KK-based survey design where all children are followed 537 up regardless of their baseline infection status (the "no selection" or *NS* design) should be

preferred as it yields unbiased results at the lowest operational cost. The "screen, select, and retest" strategy, where individuals who are egg-positive at baseline are retested based on a new pre-treatment stool sample (the *SSR* design) [21], was found to be somewhat less cost-efficient than the *NS* design. However, as previously discussed [21], because the *SSR* design will yield more egg-positive individuals than a *NS* design based on the same budget, *SSR* could still be considered for study objectives that require a minimal number of eggs or egg-positive individuals, such as genotyping to identify resistance-conferring polymorphisms.

545

546 Identifying the most cost-efficient study design for any programmatic survey

547 In the present study, the laboratory time and cost analysis were used to identify the most cost-548 efficient design for monitoring drug efficacy, but these analyses can also be used to identify the 549 most cost-effective study design for any other type of survey. Although this concept is not new 550 and has been applied in the past [39,40], the level of detail that we present for each of the different 551 FEC allows for fine-tuned cost-efficiency analysis of any programmatic survey. For instance, this 552 framework would also lend itself well to assess the cost and performance of surveys for decisions 553 about stopping or scaling down preventive chemotherapy against STH and/or assess the potential 554 value and cost-efficiency of (new) diagnostic techniques with different (hopefully better) 555 performance and throughput than FEC methods, but potentially higher reagent costs [41].

556

557 Automated egg counting would further reduce operational costs

558 As highlighted by the present study, egg counting is the most time-consuming step for KK and 559 Mini-FLOTAC (80%). An obvious cost-saving strategy that would further reduce the operational 560 costs is automated egg counting using a scanning/imaging device and artificial intelligence-based 561 egg-recognition software to identify and report egg counts.-A variety of artificial intelligence based 562 digital pathology (AI-DP) devices are currently being studied [42-46]. However, a complete AI-DP 563 device is currently not commercially available, despite the successful examples for other parasitic 564 infections (malaria: CellsCheck, http://www.biosynex.com; Loa Loa: [47]). At the time of writing, 565 FECPAK^{G2} was probably the most advanced, but automated egg-recognition on the created images 566 by existing STH egg-recognition software has proven difficult or impossible (S5 Info of Cools et al. 567 [30]). In addition, our study highlighted that due to its poor diagnostic performance [30], FECPAK^{G2} 568 is not recommended to monitor therapeutic drug efficacy in STH control programs. Despite these 569 challenges, there are ongoing investments around each of the FEC methods to progress towards 570 a complete point-of-care platform with automated egg counting and built-in data analysis [43,46]. 571

572 Strengths and limitations

573 This is the first comprehensive study that compares the operational costs between the most-used 574 FEC methods in STH surveys. It is important to note that the estimated costs are institute- and 575 context-specific, and hence the reported values should not be interpreted as absolute. However, 576 a major strength of our framework is that assumptions about costs can be easily adapted to 577 represent particular settings. Because our framework aims to compare different survey designs

and diagnostic methods, we do not consider costs that can be reasonably assumed to be the 578 579 similar across different survey designs and different FEC methods: salary for senior staff to 580 supervise the field activities, report, and analyze the data; power supplies; laboratory rent; per diems for days when work is not possible (e.g., weekends); and time required to set up and clean 581 582 laboratories and inform schools and local health authorities prior to surveys. A possibly relevant 583 simplifying assumption that we made is that survey teams work constantly without any break. This 584 may have led to a slight overestimation of the performance per cost (Fig 5) for each of the different FEC methods (more breaks because of manual egg counting) compared to FECKPAK^{G2}. Finally, it is 585 important to highlight that each of the trials were conducted by well-trained teams (and hence 586 587 the laboratory time for a less experienced team might be underestimated), and that we assumed that no individuals would be lost to follow-up. Theoretically, each of the aforementioned factors 588 589 could be included in our simulation framework, although we do not expect that the presented relative rankings of FEC methods and survey designs would be affected by the inclusion of this 590 591 additional real-life complexity. However, some of these aspects, like laboratory infrastructure, will have to be considered when comparing FEC methods with other diagnostic techniques such as 592 593 quantitative polymerase chain reaction.

594

595 Conclusion

596 We confirm that Kato-Katz is the FEC method of choice for assessing drug efficacy, but that the 597 current WHO-recommended screen and select survey design should be replaced by a no-screen 598 survey design. Our detailed analysis of laboratory time and material costs allows for a cost-

599	efficiency assessment of other FEC-based programmatic decisions as well, like decisions regarding
600	stopping and scaling down of preventive chemotherapy. In addition, the flexible and holistic design
601	of our simulation framework allows further study of alternative diagnostic techniques that aim to
602	further decrease operational costs while maintaining or improving the quality of decision-making,
603	like automated egg counting.
604	

605 **References**

GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted
 life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries
 and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
 Lancet. 2018 Nov 10;392(10159):1859-1922. doi: 10.1016/S0140-6736(18)32335-3. Erratum in:
 Lancet. 2019 Jun 22;393(10190):e44.

611 2. GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted

612 life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries

and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.

614 Lancet. 2017 Sep 16;390(10100):1260-1344. doi: 10.1016/S0140-6736(17)32130-X. Erratum in:

615 Lancet. 2017 Oct 28;390(10106):e38.

616 3. World Health Organization. Preventive chemotherapy to control soil-transmitted helminth

617 infections in at-risk population groups. 2017, World Health Organization; Geneva, Switzerland.

4. World Health Organization. Soil-transmitted helminthiases: eliminating soil-transmitted
helminthiases as a public health problem in children: progress report 2001-2010 and strategic plan
2011-2020. 2012: Geneva, Switzerland.

5. World Health Organization. Assessing the efficacy of anthelminthic drugs against
schistosomiasis and soil-transmitted helminthiases. 2013, World Health Organization Geneva.

623 6. World Health Organization. 2030 targets for soil-transmitted helminthiases control
624 programmes. 2020. World Health Organization; Geneva, Switzerland.

5. Speich B, Knopp S, Mohammed KA, Khamis IS, Rinaldi L, Cringoli G, Rollinson D, Utzinger J.
Comparative cost assessment of the Kato-Katz and FLOTAC techniques for soil-transmitted
helminth diagnosis in epidemiological surveys. Parasit Vectors. 2010 Aug 14;3:71. doi:
10.1186/1756-3305-3-71.

Leta GT, French M, Dorny P, Vercruysse J, Levecke B. Comparison of individual and pooled
diagnostic examination strategies during the national mapping of soil-transmitted helminths and
Schistosoma mansoni in Ethiopia. PLoS Negl Trop Dis. 2018 Sep 10;12(9):e0006723. doi:
10.1371/journal.pntd.0006723.

633 9. Cringoli G, Maurelli MP, Levecke B, Bosco A, Vercruysse J, Utzinger J, Rinaldi L. The Mini634 FLOTAC technique for the diagnosis of helminth and protozoan infections in humans and animals.
635 Nat Protoc. 2017 Sep;12(9):1723-1732. doi: 10.1038/nprot.2017.067.

Bekana T, Mekonnen Z, Zeynudin A, Ayana M, Getachew M, Vercruysse J, Levecke B.
Comparison of Kato-Katz thick-smear and McMaster egg counting method for the assessment of
drug efficacy against soil-transmitted helminthiasis in school children in Jimma Town, Ethiopia.
Trans R Soc Trop Med Hyg. 2015 Oct;109(10):669-71. doi: 10.1093/trstmh/trv073.

Ayana M, Vlaminck J, Cools P, Ame S, Albonico M, Dana D, et al. Modification and
optimization of the FECPAKG2 protocol for the detection and quantification of soil-transmitted
helminth eggs in human stool. PLoS Negl Trop Dis. 2018 Oct 15;12(10):e0006655. doi:
10.1371/journal.pntd.0006655.

644 12. Katz N, Chaves A, Pellegrino J. A simple device for quantitative stool thick-smear technique

in Schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo. 1972 Nov-Dec;14(6):397-400.

13. TechionGroup.com. 2017; Available from: https://www.techion.com/FECPAKG2.

647 14. Rashid MH, Stevenson MA, Waenga S, Mirams G, Campbell AJD, Vaughan JL, Jabbar A. 648 Comparison of McMaster and FECPAKG2 methods for counting nematode eggs in the faeces of 649 alpacas. Parasit Vectors. 2018 May 2;11(1):278. doi: 10.1186/s13071-018-2861-1.

650 15. Cools P, Vlaminck J, Albonico M, Ame S, Ayana M, José Antonio BP, et al. Diagnostic 651 performance of a single and duplicate Kato-Katz, Mini-FLOTAC, FECPAKG2 and qPCR for the 652 detection and quantification of soil-transmitted helminths in three endemic countries. PLoS Negl 653 Trop Dis. 2019 Aug 1;13(8):e0007446. doi: 10.1371/journal.pntd.0007446.

654 Levecke B, Cools P, Albonico M, Ame S, Angebault C, Ayana M, et al. Identifying thresholds 655 for classifying moderate-to-heavy soil-transmitted helminth intensity infections for FECPAKG2, 656 McMaster, Mini-FLOTAC and qPCR. PLoS Negl Trop Dis. 2020 Jul 2;14(7):e0008296. doi: 657 10.1371/journal.pntd.0008296.

16.

658 17. Levecke B, Anderson RM, Berkvens D, Charlier J, Devleesschauwer B, Speybroeck N, 659 Vercruysse J, Van Aelst S. Mathematical inference on helminth egg counts in stool and its applications in mass drug administration programmes to control soil-transmitted helminthiasis in 660 661 public health. Adv Parasitol. 2015 Mar;87:193-247. doi: 10.1016/bs.apar.2015.01.001.

Gass KM. Rethinking the serological threshold for onchocerciasis elimination. PLoS Negl 662 18. 663 Trop Dis. 2018 Mar 15;12(3):e0006249. doi: 10.1371/journal.pntd.0006249.

664 19. Coffeng LE, Stolk WA, Golden A, de Los Santos T, Domingo GJ, de Vlas SJ. Predictive Value of Ov16 Antibody Prevalence in Different Subpopulations for Elimination of African 665 666 Onchocerciasis. Am J Epidemiol. 2019 Sep 1;188(9):1723-1732. doi: 10.1093/aje/kwz109.

667 20. Coffeng LE, Malizia V, Vegvari C, Cools P, Halliday KE, Levecke B, Mekonnen Z, Gichuki PM,

668 Sayasone S, Sarkar R, Shaali A, Vlaminck J, Anderson RM, de Vlas SJ. Impact of Different Sampling

669 Schemes for Decision Making in Soil-Transmitted Helminthiasis Control Programs. J Infect Dis.

670 2020 Jun 11;221(Suppl 5):S531-S538. doi: 10.1093/infdis/jiz535.

671 21. Coffeng LE, Levecke B, Hattendorf J, Walker M, Denwood MJ. Survey Design to Monitor

672 Drug Efficacy for the Control of Soil-Transmitted Helminthiasis and Schistosomiasis. Clin Infect Dis.

673 2021 Jun 14;72(Suppl 3):S195-S202. doi: 10.1093/cid/ciab196.

674 22. Coffeng LE, Le Rutte EA, Munoz J, Adams E, de Vlas SJ. Antibody and Antigen Prevalence as

675 Indicators of Ongoing Transmission or Elimination of Visceral Leishmaniasis: A Modeling Study.

676 Clin Infect Dis. 2021 Jun 14;72(Suppl 3):S180-S187. doi: 10.1093/cid/ciab210.

Levecke B, Coffeng LE, Hanna C, Pullan RL, Gass KM. Assessment of the required
performance and the development of corresponding program decision rules for neglected tropical
diseases diagnostic tests: Monitoring and evaluation of soil-transmitted helminthiasis control
programs as a case study. PLoS Negl Trop Dis. 2021 Sep 14;15(9):e0009740. doi:
10.1371/journal.pntd.0009740.

Vlaminck J, Cools P, Albonico M, Ame S, Ayana M, et al. Comprehensive evaluation of stoolbased diagnostic methods and benzimidazole resistance markers to assess drug efficacy and
detect the emergence of anthelmintic resistance: A Starworms study protocol. PLoS Negl Trop Dis.
2018 Nov 2;12(11):e0006912. doi: 10.1371/journal.pntd.0006912.

Vlaminck J, Cools P, Albonico M, Ame S, Ayana M, Cringoli G, et al. Therapeutic efficacy of
albendazole against soil-transmitted helminthiasis in children measured by five diagnostic
methods. PLoS Negl Trop Dis. 2019 Aug 1:13(8):e0007471. doi: 10.1371/journal.pntd.0007471.

689 26. R Core Team (2022). R: A language and environment for statistical computing. R 690 Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/.

691 27. Vlaminck J, Cools P, Albonico M, Ame S, Chanthapaseuth T, Viengxay V, Do Trung D, et al.

Piloting a surveillance system to monitor the global patterns of drug efficacy and the emergence

693 of anthelmintic resistance in soil-transmitted helminth control programs: a Starworms study

694 protocol. Gates Open Res. 2020 Mar 10;4:28. doi: 10.12688/gatesopenres.13115.1.

Denwood MJ, Love S, Innocent GT, Matthews L, McKendrick IJ, Hillary N, et al. Quantifying
the sources of variability in equine faecal egg counts: implications for improving the utility of the
method. Vet Parasitol. 2012 Aug 13;188(1-2):120-6. doi: 10.1016/j.vetpar.2012.03.005. Epub
2012 Mar 13.

Knopp S, Mohammed KA, Speich B, Hattendorf J, Khamis IS, Khamis AN, et al. Albendazole
and mebendazole administered alone or in combination with ivermectin against Trichuris
trichiura: a randomized controlled trial. Clin Infect Dis. 2010 Dec 15;51(12):1420-8. doi:
10.1086/657310.

30. Cools P, Vlaminck J, Albonico M, Ame S, Ayana M, José Antonio BP, et al. Diagnostic performance of a single and duplicate Kato-Katz, Mini-FLOTAC, FECPAKG2 and qPCR for the detection and quantification of soil-transmitted helminths in three endemic countries. PLoS Negl Trop Dis. 2019 Aug 1;13(8):e0007446. doi: 10.1371/journal.pntd.0007446.

Barda B, Cajal P, Villagran E, Cimino R, Juarez M, Krolewiecki A, et al. Mini-FLOTAC, KatoKatz and McMaster: three methods, one goal; highlights from north Argentina. Parasit Vectors.
2014 Jun 14;7:271. doi: 10.1186/1756-3305-7-271.

Nikolay B, Mwandawiro CS, Kihara JH, Okoyo C, Cano J, Mwanje MT, et al. Understanding
Heterogeneity in the Impact of National Neglected Tropical Disease Control Programmes:
Evidence from School-Based Deworming in Kenya. PLoS Negl Trop Dis. 2015 Sep
30;9(9):e0004108. doi: 10.1371/journal.pntd.0004108.

714 33. Levecke B, Speybroeck N, Dobson RJ, Vercruysse J, Charlier J. Novel insights in the fecal egg 715 count reduction test for monitoring drug efficacy against soil-transmitted helminths in large-scale 716 treatment Trop Dis. 2011 Dec;5(12):e1427. programs. PLoS Negl doi: 717 10.1371/journal.pntd.0001427.

718 34. R-package; Available from: http://ku-awdc.github.io/eggSim.

35. Speich B, Knopp S, Mohammed KA, Khamis IS, Rinaldi L, Cringoli G, Rollinson D, Utzinger J.
Comparative cost assessment of the Kato-Katz and FLOTAC techniques for soil-transmitted
helminth diagnosis in epidemiological surveys. Parasit Vectors. 2010 Aug 14;3:71. doi:
10.1186/1756-3305-3-71.

36. Kure A, Mekonnen Z, Dana D, Bajiro M, Ayana M, Vercruysse J, Levecke B. Comparison of individual and pooled stool samples for the assessment of intensity of Schistosoma mansoni and soil-transmitted helminth infections using the Kato-Katz technique. Parasit Vectors. 2015 Sep 24;8:489. doi: 10.1186/s13071-015-1101-1.

37. Leta GT, French M, Dorny P, Vercruysse J, Levecke B. Comparison of individual and pooled
diagnostic examination strategies during the national mapping of soil-transmitted helminths and
Schistosoma mansoni in Ethiopia. PLoS Negl Trop Dis. 2018 Sep 10;12(9):e0006723. doi:
10.1371/journal.pntd.0006723.

38. Cringoli G, Maurelli MP, Levecke B, Bosco A, Vercruysse J, Utzinger J, Rinaldi L. The MiniFLOTAC technique for the diagnosis of helminth and protozoan infections in humans and animals.
Nat Protoc. 2017 Sep;12(9):1723-1732. doi: 10.1038/nprot.2017.067. Epub 2017 Aug 3.
39. Assefa LM, Crellen T, Kepha S, Kihara JH, Njenga SM, Pullan RL, Brooker SJ. Diagnostic
accuracy and cost-effectiveness of alternative methods for detection of soil-transmitted helminths

in a post-treatment setting in western Kenva. PLoS Negl Trop Dis. 2014 May 8;8(5):e2843. doi:

737 10.1371/journal.pntd.0002843.

736

40. Sturrock HJ, Gething PW, Clements AC, Brooker S. Optimal survey designs for targeting chemotherapy against soil-transmitted helminths: effect of spatial heterogeneity and costefficiency of sampling. Am J Trop Med Hyg. 2010 Jun;82(6):1079-87. doi: 10.4269/ajtmh.2010.09-0702.

Kazienga A, Coffeng LE, de Vlas SJ, Levecke B. Two-stage lot quality assurance sampling
framework for monitoring and evaluation of neglected tropical diseases, allowing for imperfect
diagnostics and spatial heterogeneity. PLoS Negl Trop Dis. 2022 Apr 8;16(4):e0010353. doi:
10.1371/journal.pntd.0010353.

42. Larsson, J. and R. Hedberg, Development of machine learning models for object
identification of parasite eggs using microscopy. 2020.

748 43. Dacal E, Bermejo-Peláez D, Lin L, Álamo E, Cuadrado D, Martínez Á, Mousa A, et al. Mobile 749 microscopy and telemedicine platform assisted by deep learning for the quantification of Trichuris 750 trichiura infection. PLoS Negl Trop Dis. 2021 Sep 7;15(9):e0009677. doi: 751 10.1371/journal.pntd.0009677.

752 44. Ephraim RK, Duah E, Cybulski JS, Prakash M, D'Ambrosio MV, Fletcher DA, et al. Diagnosis 753 of Schistosoma haematobium infection with a mobile phone-mounted Foldscope and a reversed-754 lens CellScope in Ghana. Am J Trop Med Hyg. 2015 Jun;92(6):1253-6. doi: 10.4269/ajtmh.14-0741. 755 Cringoli G, Amadesi A, Maurelli MP, Celano B, Piantadosi G, Bosco A, et al. The Kubic 45. 756 FLOTAC microscope (KFM): a new compact digital microscope for helminth egg counts. 757 Parasitology. 2021 Apr;148(4):427-434. doi: 10.1017/S003118202000219X. 758 46. Ward P, Dahlberg P, Lagatie O, Larsson J, Tynong A, Vlaminck J, Zumpe M, Ame S, Ayana 759 M, Khieu V, Mekonnen Z, Odiere M, Yohannes T, Van Hoecke S, Levecke B, Stuyver LJ. Affordable 760 artificial intelligence-based digital pathology for neglected tropical diseases: A proof-of-concept 761 for the detection of soil-transmitted helminths and Schistosoma mansoni eggs in Kato-Katz stool 762 thick smears. PLoS Negl Trop Dis. 2022 Jun 17;16(6):e0010500. doi: 763 10.1371/journal.pntd.0010500.

764 47. D'Ambrosio MV, Bakalar M, Bennuru S, Reber C, Skandarajah A, Nilsson L, et al. Point-of765 care quantification of blood-borne filarial parasites with a mobile phone microscope. Sci Transl
766 Med. 2015 May 6;7(286):286re4. doi: 10.1126/scitranslmed.aaa3480.

768 Acknowledgements

769	First and foremost, the authors would like to express their gratitude towards all children, their
770	parents, the school teachers and principals that participated in this study. Second, we wish to
771	specifically thank all the people that provided the necessary laboratory and logistic support in each
772	of the four different sampling sites. This work would not have been possible without their willful
773	participation and assistance.
774	First and foremost, the authors would like to express their gratitude towards all children, their
775	parents, the school teachers and principals that participated in this study. Second, we wish to
776	specifically thank all the people that provided the necessary laboratory and logistic support in each
777	of the four different sampling sites. This work would not have been possible without their willful
778	participation and assistance.

Supporting Information Legends

Info S1. Summary of the standard operating procedures to time the preparatory steps and the

egg counting for three FEC methods.

Info S2. Summary of the standard operating procedures to time the data entry.

Info S3. A detailed itemized cost assessment both to collect and process stool samples and for

each FEC method.

Info S4. Methods to estimate the FECs of Mini-FLOTAC and FECPAK^{G2} based on duplicate Kato-

Katz.

Info S5. Detailed description and parameterization of the simulation model.

Info S6. The calculation of the total operational costs to monitor drug efficacy

Info S7. Detail information on the calculation of the time-to-result

Fig S1. The range of school mean fecal egg counts for four levels of school prevalence for three

soil-transmitted helminths

Fig S2. The failure rate, the probability of correctly concluding reduced drug efficacy and the total survey cost across six survey designs for *Ascaris*. This figure shows the impact of the survey design and sample size on the failure rate (Panel A), probability of correctly detecting truly reduced efficacy ($prob_{reduced}$; Panel B) and the mean total survey cost ($cost_{total}$; Panel C). To gain more insights into the most cost-efficient survey design, the probability of correctly detecting reduced drug efficacy $prob_{reduced}$ was plotted as a function of the mean $cost_{total}$ (Panel D). For each of the four panels, we only consider the use of Kato-Katz in areas with low levels of *Ascaris* infection (mean FEC = 9.6 EPG). NS = no selection; SS = screen and select; SSR = screen, select, and retest. Note, for panel A, all survey designs other than SS1x2/1x2 are identical to SSR1x1/1x2.

Fig S3. The probability of correctly detecting presence of reduced drug efficacy and the total survey cost for three FEC methods across six survey designs for *Ascaris*. This figure plots the probability of correctly identifying reduced therapeutic efficacy ($prob_{reduced}$) against *Ascaris* infections as a function of the mean total survey costs ($cost_{total}$) for the three different FEC methods (Kato-Katz thick smear (KK), Mini-FLOTAC and FECPAK^{G2}; colored lines) and six survey designs (different panels). For each panel, we only consider areas that are low endemic for *Ascaris* (mean FEC = 9.6 EPG). NS = no selection; SS = screen and select; SSR = screen, select, and retest.

Fig S4. The failure rate, the probability of correctly concluding reduced drug efficacy and the total survey cost across six survey designs for *Trichuris*. This figure shows the impact of the survey design and sample size on the failure rate (Panel A), probability of correctly detecting truly reduced efficacy ($prob_{reduced}$; Panel B) and the mean total survey cost ($cost_{total}$; Panel C). To gain more insights into the most cost-efficient survey design, the probability of correctly detecting reduced drug efficacy $prob_{reduced}$ was plotted as a function of the mean $cost_{total}$ (Panel D). For each of the four panels, we only consider the use of Kato-Katz in areas with low levels of *Trichuris* infection (mean FEC = 2.8 EPG). NS = no selection; SS = screen and select; SSR = screen, select, and retest. Note, for panel A, all survey designs other than SS1x2/1x2 are identical to SSR1x1/1x2.

Fig S5. The probability of correctly detecting presence of reduced drug efficacy and the total survey cost for three FEC methods across six survey designs for *Trichuris*. This figure plots the probability of correctly identifying reduced therapeutic efficacy ($prob_{reduced}$) against *Trichuris* infections as a function of the mean total survey costs ($cost_{total}$) for the three different FEC methods (Kato-Katz thick smear (KK), Mini-FLOTAC and FECPAK^{G2}; colored lines) and six survey designs (different panels). For each panel, we only consider areas that are low endemic for *Trichuris* (mean FEC = 2.8 EPG). NS = no selection; SS = screen and select; SSR = screen, select, and retest.

Fig S6. The probability of correctly detecting presence of reduced drug efficacy and the total survey cost for six survey designs across four levels of endemicity when deploying Mini-FLOTAC. This figure plots the probability of correctly identifying reduced therapeutic efficacy $(prob_{reduced})$ as a function of the mean total survey costs $(cost_{total})$ across six survey designs for the three soil-transmitted helminth species and four levels of endemicity (see Table 1).

Fig S7. The probability of correctly detecting presence of reduced drug efficacy and the total survey cost for six survey designs across four levels of endemicity when deploying FECPAK^{G2}. This figure plots the probability of correctly identifying reduced therapeutic efficacy $(prob_{reduced})$ as a function of the mean total survey costs $(cost_{total})$ across six survey designs for the three soil-transmitted helminth species and four levels of endemicity (see Table 1).